Denali Therapeutics (NASDAQ:DNLI) Releases Quarterly Earnings Results

Denali Therapeutics (NASDAQ:DNLI) posted its quarterly earnings data on Thursday. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08, Zacks reports.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $16.56 on Friday. Denali Therapeutics has a one year low of $14.56 and a one year high of $33.33. The company has a 50 day moving average price of $21.29 and a 200 day moving average price of $24.55. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -6.00 and a beta of 1.43.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DNLI. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research report on Monday, December 16th. Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price objective for the company. Jefferies Financial Group boosted their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. cut their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. Finally, William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a research report on Friday. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Denali Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $37.42.

Insider Transactions at Denali Therapeutics

In other news, insider Carole Ho sold 12,255 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the sale, the insider now owns 178,580 shares of the company’s stock, valued at $3,610,887.60. This represents a 6.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ryan J. Watts sold 29,266 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the sale, the chief executive officer now directly owns 260,721 shares of the company’s stock, valued at $5,271,778.62. The trade was a 10.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,940 shares of company stock valued at $973,442 over the last 90 days. Corporate insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.